A phase I, open-label, dose-escalation study investigating a low-density lipoprotein receptor-related protein (LRP) 5/6 inhibitor, BI 905677, in patients with advanced solid tumors.

被引：0
|
作者：
Elez, Elena [1 ]
Lenz, Heinz-Josef [2 ]
de Jonge, Maja [3 ]
Yaeger, Rona [4 ]
Doi, Toshihiko [5 ]
Pronk, Linda [6 ]
Teufel, Michael [7 ]
Marzin, Kristell [8 ]
Tabernero, Josep [1 ]
机构：
[1] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[3] Erasmus Med Ctr Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] Natl Canc Ctr Hosp East, Chiba, Japan
[6] Boehringer Ingelheim Espana SA, Clin Dev Oncol, Madrid, Spain
[7] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[8] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT514
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
    Bendell, Johanna C.
    Hong, David S.
    Burris, Howard A., III
    Naing, Aung
    Jones, Suzanne F.
    Falchook, Gerald
    Bricmont, Patricia
    Elekes, Agnes
    Rock, Edwin P.
    Kurzrock, Razelle
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 125 - 130
  • [42] Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
    Johanna C. Bendell
    David S. Hong
    Howard A. Burris
    Aung Naing
    Suzanne F. Jones
    Gerald Falchook
    Patricia Bricmont
    Agnes Elekes
    Edwin P. Rock
    Razelle Kurzrock
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 125 - 130
  • [43] A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.
    LoRusso, Patricia
    Gounder, Mrinal M.
    Patel, Manish R.
    Yamamoto, Noboru
    Bauer, Todd Michael
    Laurie, Scott
    Grempler, Rolf
    Davenport, Teffany
    Geng, Junxian
    Rohrbacher, Maren
    Lahmar, Mehdi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors.
    Scheulen, M. E.
    Mross, K. B.
    Richly, H.
    Nokay, B.
    Frost, A.
    Scharr, D.
    Lee, K.
    Saunders, O.
    Hilbert, J.
    Fietz, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Final analysis of a phase I single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors.
    Gil, T.
    Schoffski, P.
    Awada, A.
    Dumez, H.
    Bartholomeus, S.
    Selleslach, J.
    Taton, M.
    Fritsch, H.
    Glomb, P.
    Munzert, G. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] First-in-human Phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors.
    Hollebecque, Antoine
    Soria, Jean-Charles
    Bahleda, Ratislav
    Lopez-Busto, Natividad
    Jacquet-Bescond, Anne
    Burbridge, Mike F.
    Valerie, Cattan
    Pauly, Jeanne
    Herranz, Maria
    Azaro, Analia
    Depil, Stephane
    Rodon, Jordi
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [47] Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.
    Adjei, Alex A.
    LoRusso, Patricia
    Ribas, Antoni
    Sosman, Jeffrey Alan
    Pavlick, Anna C.
    Dy, Grace K.
    Zhou, Xiaofei
    Gangolli, Esha A.
    Walker, Russell M.
    Kneissl, Michelle
    Faucette, Stephanie
    Neuwirth, Rachel
    Bozon, Viviana
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors.
    Pitot, Henry C.
    Hurwitz, Herbert
    Zanna, Claudio
    Brill, Jeffrey Mark
    Vuagniaux, Gregoire
    Rouits, Elisabeth
    Sorensen, J. Mel
    Smith, David C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Phase I, Multi-center, Open-label, Dose-escalation Study of Pasireotide LAR (PAS) in Patients With Advanced Neuroendocrine Tumors (NET)
    Strosberg, Jonathan
    Chan, Jennifer
    Mita, Alain
    Kundu, Madan
    Hermosillo, Karina
    Hu, Ke
    Wolin, Edward
    Yao, James
    PANCREAS, 2017, 46 (03) : 437 - 437
  • [50] Phase I, multi-center, open-label, dose-escalation study of pasireotide LAR (PAS) in patients with advanced neuroendocrine tumors (NET)
    Strosberg, Jonathan R.
    Chan, Jennifer A.
    Mita, Alain C.
    Kundu, Madan
    Valera, Sue-zette
    Unge, Peter
    Darstein, Christelle
    Hu, Mike
    Wolin, Edward M.
    Yao, James C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345